3
ALL3
TeraImmuneYear
3
ALL2
20231
2022DEALS // DEV.
3
ALL2
Deals1
DevelopmentsCountry
3
ALL3
U.S.A3
ALL1
Baudax Bio1
Inapplicable1
National Institutes of HealthTherapeutic Area
3
ALL3
Genetic DiseaseStudy Phase
3
ALL3
IND EnablingDeal Type
3
ALL1
Acquisition1
Agreement1
InapplicableProduct Type
3
ALL3
Cell and Gene therapyDosage Form
3
ALL3
UndisclosedLead Product
3
ALL3
TI-168Target
3
ALL3
Factor VIIILead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Baudax Bio
Deal Size : Undisclosed
Deal Type : Acquisition
Baudax Bio Acquires TeraImmune, Inc.
Details : The merger adds TeraImmune’s TI-168 asset to the Baudax portfolio, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate clotting factor VIII (FVIII) inhibitors in Hemophilia A patients.
Product Name : TI-168
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 30, 2023
Lead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Baudax Bio
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement
TeraImmune Extends CRADA for Development of Treg Expansion for Clinical Use
Details : Under the agreement, TeraImmune continues to develop cGMP-compliant manufacturing protocol for its lead candidate, TI-168, and clinical laboratory manuals designed to provide relevant tactical support for the upcoming clinical trial.
Product Name : TI-168
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 01, 2023
Lead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TI-168 is a next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitor. The primary objectives are to evaluate the safety and feasibility of TI-168 and determine the maximum tolera...
Product Name : TI-168
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : TI-168
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable